118 related articles for article (PubMed ID: 38777864)
1. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
Flanigan JA; Yasuda M; Chen CC; Li EC
Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
[TBL] [Abstract][Full Text] [Related]
2. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
5. Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.
Aslam S; Li E; Bell E; Lal L; Anderson AJ; Peterson-Brandt J; Lyman G
J Manag Care Spec Pharm; 2023 Feb; 29(2):128-138. PubMed ID: 36705281
[No Abstract] [Full Text] [Related]
6. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
7. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
8. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
10. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
[TBL] [Abstract][Full Text] [Related]
11. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Boccia R; Glaspy J; Crawford J; Aapro M
Oncologist; 2022 Aug; 27(8):625-636. PubMed ID: 35552754
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
[No Abstract] [Full Text] [Related]
14. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy.
Moreira-Pinto J; Leão I; Palmela C; Branco F; Godinho J; Simões P; Leal-Costa L; Lopes F; Faria A; Casa-Nova M; Escária A; Costa F; Galvão I; Teixeira J; Passos-Coelho JL
Oncol Res Treat; 2020; 43(11):605-612. PubMed ID: 32818937
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
[TBL] [Abstract][Full Text] [Related]
17. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
J Oncol Pract; 2015 Jan; 11(1):47-54. PubMed ID: 25491042
[TBL] [Abstract][Full Text] [Related]
18. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
20. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
